age1 — Full Portfolio
28 tracked investments · listed companies and verified rows first
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone VenturesForesite CapitalHBM Healthcare InvestmentsHBM PartnersvenBio PartnersLogos+1 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Founder)inJennifer Doudna(Founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+1 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsAgent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+6 more
Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.
BiotechLongevitySan Francisco, US
Co-investorsValhalla VenturesKleiner PerkinsSoftBank Group
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Chief Platform Officer, Co-founder)inJack O’Meara(Chief Executive Officer, Co-founder)inDave Hardwicke(Director, Head of Business Development, Co-founder)
Co-investorsBackedBlueYard CapitalEntrepreneur FirstGlobal Health Investment CorporationIaso VenturesLingotto+6 more
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)in
Co-investorsXEIA Venture Partners
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.
AI & Machine LearningBiotechDigital HealthLongevityMedical DevicesAustin, US
Adam Freund(Founder & Chief Executive Officer)inRemi-Martin Laberge(Founder and Chief Technology Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsAlumni VenturesAndreessen HorowitzGaingelsGV (Google Ventures)LifelinkMana Ventures+7 more
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtechBerkeley, US
Matt Krisiloff(CEO)inBianka Seres(President)in
Co-investorsCompoundGaingelsHOF CapitalMaiora Rebel VenturesMetaplanetSciFounders+1 more
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)in
BoardDylan Morris(Director)in
Co-investorsBold Capital PartnersCornucopian Capital ManagementCRV (Charles River Ventures)GaingelsLifespan Vision VenturesMana Ventures+3 more
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsFarvatn VentureGaingelsGRIDS CapitalLifeforce CapitalLifespan Vision VenturesMetaplanet+8 more
General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once.
BiotechDeep TechLongevity
Lada Nuzhna(CEO & Founder)in
Co-investorsAngel Collective Opportunity FundGoAhead VenturesMoth FundStreamlined Ventures
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)inMatthias PauthnerCorentine Laurin(Principal Scientist, Medicinal Chemistry)Veronica Fulton(Chief of Staff)Benji Dote(EA)Reen Ramos(EA)
Co-investorsY CombinatorFelicis VenturesFreemind InvestmentsLifespan Vision VenturesMana VenturesModi Ventures+3 more
Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan.
AI & Machine LearningBiotechHealthtechLongevity
Co-investorsFifty YearsMetaplanetPrime Movers LabStartXStreamlined VenturesW ventures+2 more
A venture capital firm focused on the longevity sector, backing founder-driven companies working on extending human healthy lifespan.
BiotechLongevity
Laura Deming(Founder)inAlex Colville(General Partner)in
Co-investors1517Collaborative Fund
Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease.
BiotechHealthtechLongevity
Celine Halioua(Founder)in
Co-investorsBain Capital VenturesBoxGroupCollaborative FundFirst Round CapitalFlucas VenturesGaingels+18 more
Loyal is a CTV and mobile publishing platform that owns and operates apps across iOS and Android while providing AI-powered ad technology through the Loyal Exchange to monetize inventory for publishers and partners.
AdTechConsumerMarketing TechMedia & EntertainmentSaaS
Tom Kenney(CEO)in
Co-investorsBlueRun VenturesTribeca Venture PartnersCrosscut VenturesBaillie Gifford
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsEcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+8 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Co-investorsBrace PharmaSanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Founder)inBlake Byers(Founder)inJacob Kimmel(Founder)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract VenturesBeyond CapitalCapital B Private Holdings+15 more
Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.
BiotechHealthtechSan Francisco, US
Aaron Friedman(Executive Officer)Vladimir Senatorov(Director)
BoardTracy Saxton(Director)James Summers(Director)Brian Slingerland(Director)
Co-investorsDolby Family Ventures
Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US
Max Hodak(Founder)inAlan Mardinly(Founder)
Co-investors885 CapitalArtis VenturesAvalanche VCBeyond CapitalConversion CapitalDuke Capital Partners+15 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Co-investorsPillar VCKdT Ventures
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsAlumni VenturesARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock+6 more
The company builds technology focused on improving patient outcomes in healthcare.
BiotechDeep TechMedical Devices
Hunter Davis(Founder)Laura Deming(Founder)
Co-investorsLux CapitalField VenturesFounders Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aperture TherapeuticsDecibel TherapeuticsMatinas / Metacrine
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




































__Twitter.png)
















































































